AE37: A novel T-cell-eliciting vaccine for breast cancer

Expert Opinion on Biological Therapy

Volumn 11, Issue 11, 2011, Pages 1543-1550

  Sears, Alan K ^a   Perez, Sonia A ^b   Clifton, Guy T ^a   Benavides, Linda C ^a   Gates, Jeremy D ^a   Clive, Kevin S ^a   Holmes, Jarrod P ^c   Shumway, Nathan M ^a   Van Echo, David C ^d   Carmichael, Mark G ^e   Ponniah, Sathibalan ^f   Baxevanis, Constantin N ^b   Mittendorf, Elizabeth A ^g   Papamichail, Michael ^b   Peoples, George E ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b SAINT SAVVAS HOSPITAL   (Greece)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^d LANDSTUHL REGIONAL MEDICAL CENTER   (Germany)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f Cancer Vaccine Development Laboratory   (United States)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

AE36 peptide; AE37 vaccine; Breast cancer; Cancer vaccines; Ii Key hybrid; Prostate cancer

Indexed keywords

AE 27; AE 36; AE 37 VACCINE; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; BLISTER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; COUGHING; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; JOINT STIFFNESS; MYALGIA; NAUSEA; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; RHINITIS;

ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 80053643169     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.616889     Document Type: Article

References (32)

1. Mittendorf EA, Peoples GE, Singletary SE. Breast cancer vaccines, promise for the future or pipe dream? Cancer 2007;11:1677-86 (Pubitemid 47557292)
2. Gutierrez C, Schiff R. HER2 biology, detection, and clinical implications. Arch Pathol Lab Med 2010;135:55-62
3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12 (Pubitemid 19147683)
4. Mabuchi S, Morishige K, Kimura T. Use of monoclonal antibodies in the treatment of ovarian cancer. Curr Opin Obstet Gynecol 2010;22:3-8
5. Neto AS, Tobias-Machado M, Wroclawski ML, et al. HER-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol 2010;184:842-50
6. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010;376:687-97
7. Kimura K, Sawada T, Komatsu M, et al. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 2006;12:4925-32 (Pubitemid 44338580)
8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84 (Pubitemid 41464706)
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72 (Pubitemid 41464705)
10. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36 (Pubitemid 46039831)
11. Baxevanis CN, Voutsas IF, Gritzapis AD, et al. HER-2/neu as a target for cancer vaccines. Immunotherapy 2010;2:213-26
12. Benavides LC, Gates JD, Carmichael MG, et al. The impact of HER2/neu expression level on response to the E75 vaccine: from the U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2009;15:2895-904
13. Peoples GE, Holmes JP, Hueman MT, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008;14:797-803 (Pubitemid 351231162)
14. Holmes JP, Clifton GT, Patil R, et al. Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine. Cancer 2011;117:463-71
15. Carmichael MG, Benavides LC, Holmes JP, et al. Results of the first Phase I clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients. Cancer 2010;116:292-301
16. Brooke Army Medical Center. Vaccine Therapy in Treating Patients With Breast Cancer. ClinicalTrials.gov NCT00524277 Available from: http://clinicaltrials.gov/ct2/show/NCT00524277? term=NCT00524277&rank=1
17. Perez SA, von Hofe E, Kallinteris NL, et al. A new era in anticancer peptide vaccines. Cancer 2010;116:2071-80
18. Fred Hutchinson Cancer Research Center. Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer. ClinicalTrials.gov NCT00343109 Available from: http://clinicaltrials.gov/ct2/ show/NCT00343109? term=NCT00343109&rank=1
19. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5:1289-997
20. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with the HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32 (Pubitemid 34575634)
21. Humphreys RE, Adams S, Koldzic G, et al. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 2000;18:2693-7 (Pubitemid 30211577)
22. Kallinteris NL, Lu X, Blackwell CE, et al. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent vaccines. Expert Opin Biol Ther 2006;6:1311-21 (Pubitemid 44875685)
23. Voutsas IF, Gritzapis AD, Mahaira LG, et al. Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer 2007;121:2031-41 (Pubitemid 47463167)
24. Sotiriadou NN, Kallinteris NL, Gritzapis AD, et al. Ii-key/HER-2/neu (776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunol Immunother 2007;56:601-13 (Pubitemid 46348728)
25. Holmes JP, Benavides LC, Gates JD, et al. Results of the first Phase I clinical trial of the novel Ii-key hybrid preventative HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008;26:3426-33
26. Benavides LC, Sears AK, Gates JD, et al. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. Expert Rev Vaccines 2011;10:201-10
27. Merlo A, Casalini P, Carcangiu ML, et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009;27:1735-6
28. Gates JD, Clifton GT, Benavides LC, et al. Circulating regulatory T cells (CD4 +CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide. Vaccine 2010;28:7476-82
29. Perez SA, Kallinteris NL, Bisias S, et al. Results from a Phase I clinical study of the novel Ii-Key/HER-2/neu (776-790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res 2010;16:3495-506
30. Banham AH. Cell-surface IL-7 receptor expression facilitates the purification of FOXP3+ regulatory T cells. Trends Immunol 2006;27:541-4 (Pubitemid 44780852)
31. Sears AK, Clifton GT, Perez SA, et al. Vaccine-specific immunologic responses to the novel Ii-key hybrid HER-2/neu peptide (AE37) vaccine in a Phase II clinical trial. Ann Surg Oncol 2011;18(Suppl 1):S57-8
32. Sears AK, Clifton GT, Van Echo DC, et al. Circulating regulatory T cells (CD4 +CD25highCD127low) decrease in breast cancer patients after vaccination with a modified HER-2/neu HLA class II peptide (AE37) vaccine [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; Orlando, Florida. Philadelphia (PA): 2011 Apr 2-6; AACR; 2011.